Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA
reductase inhibitor (ie statin) with particularly strong inhibitory effects on hepatic cholesterol …

Since the discovery of the LDL receptor in 1973 by Brown and Goldstein as a causative
protein in hypercholesterolemia, tremendous amounts of effort have gone into finding ways …

Background COVID-19 is a worldwide public health concern. Disruptions in the drug market
are expected and shortages might worsen. Community pharmacies can contribute to early …

Purpose Combination therapy with ezetimibe and statins is recommended in cases of statin
intolerance or insufficiency. The objective of this study was to compare the efficacy and …

Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–
related morbidity and mortality. However, a large proportion of patients cannot attain the …

Introduction Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …

Inflammatory bowel disease [IBD] has a multifactorial origin and originates from a complex
interplay of environmental factors with the innate immune system at the intestinal epithelial …

Background Adding ezetimibe to high-intensity statin therapy is used for additional lowering
of low-density lipoprotein cholesterol (LDL-C); however, there are little data on the efficacy of …

Statins are first‑line agents used in patients with dyslipidemia, which show established
benefits in reducing low‑density lipoprotein cholesterol (LDL‑C) levels and decreasing the …

Introduction: Reducing low-density lipoprotein cholesterol (LDL-C) with lipid-lowering
therapies has been associated with a decrease in the frequency of cardiovascular events …